Drug Topics
NOVEMBER 23, 2023
While data has associated insufficient sleep with increased risks of hypertension, cardiovascular disease, and disordered glucose metabolism, a potential source of insulin resistance and type 2 diabetes, much of this data was performed on male participants or evaluated short-term sleep restriction.
STAT
NOVEMBER 23, 2023
Reports of increased respiratory disease among children in China have put disease watchers elsewhere on alert, triggering anxiety that the outbreak — if it is indeed one outbreak — holds uncomfortable echoes of the start of the Covid-19 pandemic. But at present, a number of experts say the activity has a likely explanation: China’s population, especially its young children, probably developed significant immunological susceptibility to a range of respiratory pathogens d
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 23, 2023
Pediatric individuals that are higher risk for APS must be followed to better understand affects
pharmaphorum
NOVEMBER 23, 2023
AstraZeneca joins KRAS push in cancer with Chinese deal Phil.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
NOVEMBER 23, 2023
Following the UK government’s recent announcement of a £520 million funding boost for UK manufacturing, a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland will develop innovative and sustainable techniques for these medicines. According to the Centre for Process Innovation (CPI), oligonucleotides therapeutics use short, chemically synthesised fragments of DNA or RNA to modulate protein expression and ultimately treat the underlying cause of disease.
pharmaphorum
NOVEMBER 23, 2023
How can the value of patient engagement be quantified and measured? Mike.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 23, 2023
Exploring the impact of patient flow forecasting on the patient and the HCP Mike.
European Pharmaceutical Review
NOVEMBER 23, 2023
Last month at CPHI Barcelona 2023 , EPR interviewed Mohamed Noor, Digitalization Manager at the National Institute for Bioprocessing Research and Training ( NIBRT ). During the conversation, Noor shed light on how digitalisation is impacting the biopharmaceutical industry. Additionally, he explored the trends, challenges and opportunities for process analytical technology (PAT).
pharmaphorum
NOVEMBER 23, 2023
The power of data science platforms to cut through the complexity of modern-day clinical research Mike.
Outsourcing Pharma
NOVEMBER 23, 2023
Cradle, the biotech startup using generative AI to help scientists design and engineer proteins, has raised $24 million in Series A funding.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
NOVEMBER 23, 2023
How birth tissue donations are fuelling the cell therapy revolution Mike.
Outsourcing Pharma
NOVEMBER 23, 2023
German CDMO Adragos Pharma has its eye on expansion and is continually branching out into new markets.
pharmaphorum
NOVEMBER 23, 2023
Supercharge your supply chain: Harnessing AI to gain competitive advantage Mike.
Outsourcing Pharma
NOVEMBER 23, 2023
Healthcare breakthroughs have long-standing barriers when it comes to unlocking the powerful insights trapped in medical imaging data.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
NOVEMBER 23, 2023
Novo Nordisk will invest €2.1bn in French manufacturing site Phil.
Pharma Times
NOVEMBER 23, 2023
Both companies will use their platforms to accelerate drug discovery and development - News - PharmaTimes
pharmaphorum
NOVEMBER 23, 2023
InDex craters on phase 3 ulcerative colitis failure Phil.
Pharma Times
NOVEMBER 23, 2023
ADP101 is an oral immunotherapy to treat multi-food and single-food allergies - News - PharmaTimes
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
NOVEMBER 23, 2023
Lord James O’Shaughnessy has welcomed the UK government’s official response to his review of commercial clinical trials, saying there have been a number of positive developments since it was published in the spring.
Pharmaceutical Technology
NOVEMBER 23, 2023
EirGenix and Sandoz's biosimilar has been approved for all the indications as the reference biologic, Roche’s Herceptin.
BioPharm
NOVEMBER 23, 2023
Chris Spivey, editorial director for Pharmaceutical Technology and Biopharm International, spoke with Concetto Andrea Rizza, Marketing and Communications manager, ICE Pharma, on sustainability and ICE’s green approach at CPhI Barcelona 2023.
Pharmaceutical Technology
NOVEMBER 23, 2023
The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.
Pharmafile
NOVEMBER 23, 2023
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination with ruxolitinib, a JAK inhibitor for the treatment of JAK inhibitor-naïve patients with myelofibrosis. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in the proportion of patients achieving at […] The post MorphoSys shares phase 3 trial results for pelabresib in myelofibro
BioPharm
NOVEMBER 23, 2023
Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.
Pharmafile
NOVEMBER 23, 2023
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis. The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 […] The post Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment appeared first on Pharmafile.
Pharmaceutical Technology
NOVEMBER 23, 2023
Simcere will have the rights to develop and commercialise rademikibart in mainland China, Macau, Taiwan, and Hong Kong.
BioPharm
NOVEMBER 23, 2023
UK industry body, ABPI, has responded positively to the recent Autumn Statement.
Hospital Pharmacy Europe
NOVEMBER 23, 2023
Zanubrutinib (brand name Brukinsa) has been granted marketing authorisation by the European Commission (EC) for use in combination with obinutuzumab for eligible patients with follicular lymphoma, its manufacturer BeiGene has announced. This highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor is now approved for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior lines of systemic therapy.
Pharmaceutical Technology
NOVEMBER 23, 2023
Syncona has signed a definitive agreement to acquire clinical-stage biotechnology company Freeline Therapeutics
Hospital Pharmacy Europe
NOVEMBER 23, 2023
A low-carbon salbutamol metered-dose inhaler (MDI) that could reduce greenhouse gas emissions from use of the inhaler by around 90% is to advance to phase 3 trials in the first half of 2024. If successful, the phase 3 trials will support regulatory submissions in 2025, its manufacturer GSK has said. The low-carbon salbutamol inhaler uses a next-generation propellant technology, which has been under technical development for several years and has been tested extensively to ensure suitability for
Pharmaceutical Technology
NOVEMBER 23, 2023
China’s NMPA has accepted NDA for AnHeart Therapeutics taletrectinib to treat locally advanced or metastatic ROS1-positive NSCLC.
Hospital Pharmacy Europe
NOVEMBER 23, 2023
The importance of pharmacists mitigating antimicrobial resistance (AMR) through antimicrobial stewardship is the subject of an updated policy statement published by the International Pharmaceutical Federation (FIP) as it calls for action this World Antimicrobial Resistance Awareness Week. The statement of policy emphasises the vital role of pharmacists in leading the fight against AMR and encourages collaboration between governments, policymakers and national pharmacy organisations.
Pharmaceutical Technology
NOVEMBER 23, 2023
When expectant mothers are diagnosed with gestational diabetes mellitus (GDM) they often feel anxious and need extra support.
Expert insights. Personalized for you.
247 
Let's personalize your content